DrugPatentWatch Database Preview
Patent: 9,226,961
Summary for Patent: 9,226,961
| Title: | Antibody formulation |
| Abstract: | The invention provides a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.0 to about 6.0, and an optional surfactant, methods for making such a formulation, and methods of using such a formulation. |
| Inventor(s): | Gokarn; Yatin R. (Thane, IN), Kamerzell; Timothy J. (Overland Park, KS), Li; Megan (San Francisco, CA), Cromwell; Mary (Redwood City, CA), Liu; Hong (Foster City, CA) |
| Assignee: | Genentech, Inc. (South San Francisco, CA) |
| Application Number: | 14/046,909 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,226,961 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,226,961
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2029-12-21 | RX | Orphan | search |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 002 | 2004-02-26 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2029-12-21 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 9,226,961
| Country | Patent Number | Publication Date |
|---|---|---|
| Argentina | 079556 | Feb 01, 2012 |
| Australia | 2010339770 | Feb 12, 2015 |
| Australia | 2010339770 | Jun 21, 2012 |
| Brazil | 112012013093 | Dec 12, 2017 |
| >Country | >Patent Number | >Publication Date |
